Oral administration of heat-killed Lactobacillus brevis SBC8803 ameliorates alcoholic liver disease in ethanol-containing diet-fed C57BL/6N mice.
- 2008-12
- International Journal of Food Microbiology 128(2)
- S. Segawa
- Yoshihisa Wakita
- H. Hirata
- J. Watari
- PubMed: 18976829
- DOI: 10.1016/j.ijfoodmicro.2008.09.023
Abstract
We examined the effect of heat-killed Lactobacillus brevis (L. brevis) SBC8803 on the development of alcoholic liver disease using ethanol-containing diet-fed mice. Heat-killed L. brevis was orally administered at a dose of 100 or 500 mg/kg once a day for 35 days. Alcoholic liver injury was examined by measuring the activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in a serum, and the alcoholic fatty liver was assessed from the content of triglyceride (TG) and total cholesterol in the liver. Quantitative RT-PCR was used to examine mRNA expression of tumor necrosis factor (TNF)-alpha, sterol regulatory element-binding protein (SREBP)-1, SREBP-2, and peroxisome proliferator-activated receptor alpha (PPARalpha) in the liver, as well as E-cadherin, Zonula occludens 1 (ZO-1), and heat shock protein (Hsp) 25 in the small intestine. Oral administration of L. brevis significantly inhibited an increase in the level of serum ALT and AST, as well as the content of TG and total cholesterol in the liver caused by ethanol intake. L. brevis supplementation suppressed the overexpression of TNF-alpha, SREBP-1, and SREBP-2 mRNA in the liver induced by ethanol intake and up-regulated the expression of Hsp25 mRNA in the small intestine. These results suggest that L. brevis ameliorated the ethanol-induced liver injury and the fatty liver by suppressing the up-regulation of TNF-alpha and SREBPs in the liver. We speculate that the inhibition of TNF-alpha and SREBPs up-regulation by L. brevis is due to the inhibition of gut-derived endotoxin migration into the liver through the enhancement of intestinal barrier function by the induction of cytoprotective Hsps.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Lactobacillus brevis | Improved Intestinal Barrier Function | Beneficial | Moderate |
Lactobacillus brevis | Increased Expression of Heat Shock Protein 25 | Beneficial | Small |
Lactobacillus brevis | Reduced Elevated Liver Enzymes | Beneficial | Moderate |
Lactobacillus brevis | Reduced Liver Triglyceride Content | Beneficial | Moderate |
Lactobacillus brevis | Reduced TNF-alpha Gene Expression | Beneficial | Moderate |
Lactobacillus brevis HA-112 | Increased Small Intestine Hsp25 mRNA Expression | Beneficial | Small |
Lactobacillus brevis HA-112 | Reduced Liver Enzyme Levels | Beneficial | Large |
Lactobacillus brevis HA-112 | Reduced TNF-α Levels | Beneficial | Moderate |
Lactobacillus brevis KABP™-052 | Improved Intestinal Barrier Function | Beneficial | Moderate |
Lactobacillus brevis KABP™-052 | Reduced Inflammation Levels | Beneficial | Moderate |
Lactobacillus brevis KABP™-052 | Reduced Liver Enzyme Levels | Beneficial | Large |
Lactobacillus brevis KABP™-052 | Reduced Liver Fat | Beneficial | Large |
Lactobacillus brevis LB01 | Increased Small Intestine Hsp25 mRNA Expression | Beneficial | Small |
Lactobacillus brevis LB01 | Reduced Liver Cholesterol | Beneficial | Large |
Lactobacillus brevis LB01 | Reduced Liver Enzyme Levels | Beneficial | Large |
Lactobacillus brevis LB01 | Reduced Liver Triglycerides | Beneficial | Large |
Lactobacillus brevis LB01 | Reduced SREBP-1 Expression | Beneficial | Moderate |
Lactobacillus brevis LB01 | Reduced SREBP-2 Expression | Beneficial | Moderate |
Lactobacillus brevis LB01 | Reduced TNF-alpha Gene Expression | Beneficial | Moderate |
Lactobacillus brevis Lbr-35 | Improved Intestinal Barrier Function | Beneficial | Moderate |
Lactobacillus brevis Lbr-35 | Reduced Liver Enzyme Levels | Beneficial | Large |
Lactobacillus brevis MAK11L82B | Improved Intestinal Barrier Function | Beneficial | Moderate |
Lactobacillus brevis MAK11L82B | Reduced Hepatic Fat Accumulation | Beneficial | Large |
Lactobacillus brevis MAK11L82B | Reduced Inflammatory Marker Expression | Beneficial | Moderate |
Lactobacillus brevis MAK11L82B | Reduced Liver Enzyme Levels | Beneficial | Large |
Lactobacillus brevis SBC8803 | Increased Small Intestine Hsp25 mRNA Expression | Beneficial | Small |
Lactobacillus brevis SD-5214 | Increased Small Intestine Hsp25 mRNA Expression | Beneficial | Small |
Lactobacillus brevis SD-5214 | Reduced Liver Injury Indicators | Beneficial | Large |
Lactobacillus brevis UALbr-02 | Improved Intestinal Barrier Function | Beneficial | Moderate |
Lactobacillus brevis UALbr-02 | Improvement in Alcoholic Liver Disease | Beneficial | Large |
Lactobacillus brevis UALbr-02 | Reduced Inflammatory Markers | Beneficial | Moderate |
Lactobacillus brevis VPro 18 | Reduced AST Levels | Beneficial | Large |
Lactobacillus brevis VPro 18 | Reduced Aminotransferase Levels | Beneficial | Large |
Lactobacillus brevis VPro 18 | Reduced Liver Cholesterol Content | Beneficial | Large |
Lactobacillus brevis VPro 18 | Reduced Liver Fat Content | Beneficial | Large |
Lactobacillus brevis VPro 18 | Reduced Liver SREBP-1 mRNA Levels | Beneficial | Moderate |
Lactobacillus brevis VPro 18 | Reduced Liver SREBP-2 mRNA Levels | Beneficial | Moderate |
Lactobacillus brevis VPro 18 | Reduced TNF-α Levels | Beneficial | Moderate |